A Phase 1 interventional study of PF-07054894 and Placebo in Ulcerative Colitis, sponsored by Pfizer. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Colitis, Ulcerative by Pfizer — 3 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 19th largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 35th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States
Ages 18–64
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 129 across the 24 interventional studies, 276 across the 16 observational. Of the 32 that completed or were terminated, 26 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
3 of the studies in Colitis, Ulcerative by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT06294925PfizerA Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis | 2027-05-13 |
| NCT06398626PfizerAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Colitis, Ulcerative by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A (moderate to severe): Must have a 5 to 9 score on the modified mayo score, including an endoscopy subscore of at least 2. Part B (mild to moderate): Participants with mMS of 4 to 6, ES of ≥2 and RB score of ≥1
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral PF-07054894
Drug: PF-07054894
Matched Placebo
Drug: Placebo
Oral
Placebo
Part A: Proportion of participants achieving clinical remission at Week 12 in participants with moderate to severe UC.
Clinical remission based on modified Mayo Score is defined as endoscopic subscore equal 0 or 1 (without friability), stool frequency subscore equal 0 or 1, and rectal bleeding subscore equal 0
Time frame: Week 12
Part B: Percent change from baseline in the mMS in participants with mild to moderate UC.
Time frame: Week 12
Part A: Proportion of participants achieving improvement in endoscopic appearance at Week 12
Endoscopic improvement is defined as a Mayo endoscopic subscore of ≤1 (without friability)
Time frame: Week 12
Part A: Proportion of participants with clinical remission at Week 12
Clinical Remission defined by Total Mayo Score ≤2 and no individual subscore \>1 and rectal bleeding subscore of 0
Time frame: Week 12
Part B: Proportion of participants achieving clinical remission at Week 12
Clinical Remission based on modified Mayo Score is defined as endoscopic subscore 0 or 1 (without friability), stool frequency subscore 0 or 1, and rectal bleeding subscore 0.
Time frame: Week 12
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Nov 2022 to primary completion in Nov 2025, 36 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-07054894